WO2021100056A1 - Prolonged release pharmaceutical compositions of ivabradine - Google Patents
Prolonged release pharmaceutical compositions of ivabradine Download PDFInfo
- Publication number
- WO2021100056A1 WO2021100056A1 PCT/IN2020/050753 IN2020050753W WO2021100056A1 WO 2021100056 A1 WO2021100056 A1 WO 2021100056A1 IN 2020050753 W IN2020050753 W IN 2020050753W WO 2021100056 A1 WO2021100056 A1 WO 2021100056A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- less
- ivabradine
- hours
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Definitions
- the present disclosure relates to prolonged release pharmaceutical compositions of ivabradine and pharmaceutically acceptable salts thereof.
- Ivabradine is a medication used for the symptomatic management of stable heart- related chest pain and heart failure not fully managed by beta blockers.
- ivabradine is rapidly released from tablet.
- a peak plasma level reached in about 1 hour under fasting conditions.
- ivabradine The effectiveness of ivabradine is limited by its high solubility, low mean residence time, and short half-life. Accordingly, there exists a need for pharmaceutical compositions of ivabradine which provide prolonged release of drug and maintain the blood drug concentration in therapeutic window for, preferably, at least 24 hours thereby avoiding the complications of fast dissolution.
- solid prolonged release compositions comprising ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof.
- the ivabradine of the disclosed compositions may have a peak plasma concentration between about 3 hours to about 8 hours after administration of the composition to a subject in the fasting state or between about 4 hours to about 10 hours after administration of the composition to a subject in the fed state.
- the prolonged release compositions comprise about 3 to about 12% by weight of ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof, about 35% to about 65% by weight of polymer selected from hydroxypropyl methyl cellulose, polyvinyl acetate/polyvinylpyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose or mixtures thereof, about 20% to about 60% by weight of dibasic calcium phosphate, and about 0.25% to about 1.25% by weight of magnesium stearate.
- FIGS. 1A-1B are graphs of the mean plasma concentration versus time for ivabradine plotted linearly (FIG. 1A) and semi logarithmically (FIG. IB).
- FIGS. 2A-2B are graphs of the mean plasma concentration versus time for N- desmethyl ivabradine plotted linearly (FIG. 2A) and semi logarithmically (FIG. 2B).
- FIG. 3 is a box plot of the mean heart rate (HR) change from baseline to 3 months following treatment with ivabradine immediate release or prolonged release tablets.
- the boxes represent the inter quartile range (IQR).
- the symbols inside the boxes are the mean values and those outside the boxes are data values beyond ⁇ 1.5 IQR. Whiskers are drawn at minimum and maximum data points between the ⁇ 1.5 IQR.
- compositions of ivabradine can be used for once-a-day administration of ivabradine.
- the modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (for example, it includes at least the degree of error associated with the measurement of the particular quantity).
- the modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints.
- the expression “from about 2 to about 4” also discloses the range “from 2 to 4.”
- the term “about” may refer to plus or minus 10% of the indicated number.
- “about 10%” may indicate a range of 9% to 11%, and “about 1” may mean from 0.9- 1.1.
- Other meanings of “about” will be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.
- each intervening number there between with the same degree of precision is explicitly contemplated.
- the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
- Prolonged release refers to any formulation or composition that comprises an active drug and which is formulated to release the drug for longer duration of time and to provide a longer duration of pharmacological response after administration of the composition than is ordinarily not experienced after administration of a corresponding immediate release formulation comprising the same drug in the same amount.
- Prolonged release formulations include, inter alia, those formulations described elsewhere as “controlled release”, “delayed release”, “sustained release”, “extended release”, “programmed release”, “time release,” “modified release” and/or “rate controlled” formulations or compositions. Further for the purposes of this disclosure, “prolonged release” refers to release of an active pharmaceutical agent over a prolonged period of time, such as for example over a period of 8, 12, 16 or 24 hours.
- pharmaceutically acceptable is meant a carrier comprised of a material that is not biologically or otherwise undesirable.
- ivabradine as used in the disclosure is meant to cover ivabradine in the form of free base or its pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof.
- the term also includes all polymorphic forms, whether crystalline or amorphous.
- the chemical name for ivabradine is 3-(3- ⁇ [((7S)-3,4-dimethoxybicyclo[4.2.0]octa-l,3,5-trien-7yl)methyl] methyl amino ⁇ propyl)-l,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one, hydrochloride.
- the molecular formula is C 27 H 36 N 2 O 5 , HC1, and the molecular weight (free base + HC1) is 505.1.
- the chemical structure of ivabradine is as follows:
- the present disclosure provides solid prolonged release compositions comprising ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof.
- the ivabradine of the disclosed compositions may have a peak plasma concentration between about 3 hours to about 8 hours after administration of the composition to a subject in the fasting state or between about 4 hours to about 10 hours after administration of the composition to a subject in the fed state.
- the present disclosure also provides a solid prolonged release composition
- a solid prolonged release composition comprising:
- the solid prolonged release composition comprises polymer selected from hydroxypropyl methyl cellulose, polyvinyl acetate/polyvinylpyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose or mixtures thereof.
- the solid prolonged release composition comprises about 3% to about 12% by weight of ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof; about 35% to about 65% by weight of polymer selected from hydroxypropyl methyl cellulose, polyvinyl acetate/polyvinylpyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose or mixtures thereof; optionally one or more pharmaceutically acceptable carriers.
- the % by weight is based on total weight of the composition.
- the prolonged release composition can be coated with a film.
- the composition is coated with about 2% to about 4% by weight of a film coating material.
- the film coating can be any of those known in the art.
- the film coating material can be a mixture of titanium dioxide, polyethylene glycol, hydroxypropyl methyl cellulose, glycerin, yellow iron oxide non-irradiated, and red iron oxide non-irradiated.
- the composition is a solid dosage form that includes, but is not limited to, tablets, pills, dragees, caplets, mini-tablets, pellets, granules, capsule, capsule filled with mini tablets or pellets or combinations thereof.
- the composition is a tablet.
- the present disclosure provides a solid prolonged release composition comprising: ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof; polymer selected from hydroxypropyl methyl cellulose, polyvinyl acetate/ polyvinylpyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose or mixtures thereof; dibasic calcium phosphate; and magnesium stearate.
- the prolonged release composition may include about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11% or about 12% by weight of ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof.
- the composition comprises about 8% by weight of ivabradine, N-desmethyl ivabradine, or a pharmaceutical salt thereof.
- the prolonged release composition comprises hydroxypropyl methyl cellulose.
- the composition may comprise about 35% to about 65% by weight hydroxypropyl methyl cellulose. In some embodiments, the composition comprises about 35%, about 40%, about 45%, about 50%, about 55%, about 60% or about 65% by weight hydroxypropyl methyl cellulose. In certain embodiments, the composition comprises about 50% by weight of hydroxypropyl methyl cellulose.
- the prolonged release composition may include about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 20% to about 30%, about 30% to about 60%, about 30% to about 50%, about 30% to about 40%, about 40% to about 50%, about 40% to about 60% or about 50% to about 60% by weight dibasic calcium phosphate. In some embodiments, the composition comprises about 41% by weight of dibasic calcium phosphate.
- the prolonged release composition may include about 0.25%, about 0.5%, about 0.75%, about 1.00%, or about 1.25% by weight of magnesium stearate. In certain embodiments, the composition comprises about 1% by weight magnesium stearate.
- the present disclosure provides a composition
- ivabradine is present in an amount ranging from 5.39 to 8.09% by weight
- hydroxypropyl methyl cellulose is present in an amount ranging from 25 to 55% by weight
- dibasic calcium phosphate is present in an amount ranging from 35.91 to 65.91% by weight
- magnesium stearate is present in an amount of 1% by weight.
- the present disclosure provides a composition comprising: about 8% by weight of ivabradine hydrochloride; about 50% by weight of hydroxypropyl methyl cellulose; about 41% by weight of dibasic calcium phosphate; and about 1% by weight of magnesium stearate.
- the percentage (%) by weight is based on total weight of the composition.
- the present disclosure further provides a solid prolonged release composition
- a solid prolonged release composition comprising: ivabradine in an amount ranging from 7.81 to 8.09% by weight; hydroxypropyl methyl cellulose in an amount ranging from 48.31 to 50% by weight; dibasic calcium phosphate in an amount ranging from 40.01 to 40.41% by weight; magnesium stearate is present in an amount of 0.97-1% by weight; and colourant in an amount of 2.90% by weight.
- the prolonged release composition may further include pharmaceutically acceptable carriers.
- pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material, or formulation auxiliary of any type.
- materials which can serve as pharmaceutically acceptable carriers are sugars such as, but not limited to, lactose, glucose and sucrose; starches such as, but not limited to, com starch and potato starch; cellulose and its derivatives such as, but not limited to, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as, but not limited to, cocoa butter and suppository waxes; oils such as, but not limited to, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols; such as propylene glycol; esters such as, but not limited to, ethyl oleate and ethyl laurate; agar; buffering agents such as, but not limited to, magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic sa
- Carriers for systemic (i.e., oral) administration typically include at least one of diluents, lubricants, binders, disintegrants, colorants, flavors, sweeteners, antioxidants, preservatives, glidants, solvents, suspending agents, wetting agents, surfactants, combinations thereof, and others.
- Suitable diluents include sugars such as glucose, lactose, dextrose, and sucrose; diols such as propylene glycol; calcium carbonate; sodium carbonate; sugar alcohols, such as glycerin; mannitol; and sorbitol.
- the amount of diluent(s) in a systemic or topical composition is typically about 50% to about 90% by weight.
- Suitable lubricants include silica, talc, stearic acid and its magnesium salts and calcium salts, calcium sulfate; and liquid lubricants such as polyethylene glycol and vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma.
- the amount of lubricant(s) in a systemic or topical composition is typically about 5% to about 10% by weight.
- Suitable binders include polyvinyl pyrrolidone; magnesium aluminum silicate; starches such as corn starch and potato starch; gelatin; tragacanth; and cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, methylcellulose, and microcrystalline cellulose.
- the amount of binder(s) in a systemic composition is typically about 5% to about 50% by weight.
- Suitable disintegrants include agar, alginic acid and the sodium salt thereof, effervescent mixtures, croscarmellose, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, clays, and ion exchange resins.
- the amount of disintegrant(s) in a systemic or topical composition is typically about 0.1% to about 10% by weight.
- Suitable colorants include a colorant such as an FD&C dye. When used, the amount of colorant in a systemic or topical composition is typically about 0.005% to about 0.1% by weight.
- Suitable flavors include menthol, peppermint, and fruit flavors. The amount of flavor(s), when used, in a systemic or topical composition is typically about 0.1% to about 1.0% by weight.
- Suitable sweeteners include aspartame and saccharin.
- the amount of sweetener(s) in a systemic or topical composition is typically about 0.001% to about 1% by weight.
- Suitable antioxidants include butylated hydroxyanisole (“BHA”), butylated hydroxytoluene (“BHT”), and vitamin E.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- the amount of antioxidant(s) in a systemic or topical composition is typically about 0.1% to about 5% by weight.
- Suitable preservatives include benzalkonium chloride, methyl paraben and sodium benzoate.
- the amount of preservative(s) in a systemic or topical composition is typically about 0.01% to about 5% by weight.
- Suitable glidants include silicon dioxide.
- the amount of glidant(s) in a systemic or topical composition is typically about 1% to about 5% by weight.
- Suitable solvents include water, isotonic saline, ethyl oleate, glycerine, hydroxylated castor oils, alcohols such as ethanol, and phosphate buffer solutions.
- the amount of solvent(s) in a systemic or topical composition is typically from about 0 to about 100% by weight.
- Suitable suspending agents include AVICEL RC-591 (from FMC Corporation of Philadelphia, Pa.) and sodium alginate.
- the amount of suspending agent(s) in a systemic or topical composition is typically about 1% to about 8% by weight.
- Suitable surfactants include lecithin, Polysorbate 80, and sodium lauryl sulfate, and the TWEENS from Atlas Powder Company of Wilmington, Del.
- Suitable surfactants include those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, 1992, pp. 587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp. 335-337; and McCutcheon's Volume 1, Emulsifiers & Detergents, 1994, North American Edition, pp. 236-239.
- the amount of surfactant(s) in the systemic or topical composition is typically about 0.1% to about 5% by weight.
- compositions can be coated by conventional methods, typically with pH or time-dependent coatings, such that a disclosed compound is released in the gastrointestinal tract in the vicinity of the desired application, or at various points and times to extend the desired action.
- the coatings typically include one or more components selected from cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, EUDRAGIT® coatings (available from Evonik Industries of Essen, Germany), waxes and shellac.
- the present disclosure provides a process for preparing the solid prolonged release composition, wherein the process comprises a direct compression method.
- the process for preparing the disclosed composition comprises preparing a tablet dosage form, comprising:
- step (b) compressing the tablet formulation obtained in step (a) to form a compressed tablet dosage form.
- ivabradine After administration of the prolonged release composition to a subject in the fasting state, ivabradine may have a peak plasma concentration between about 3 hours to about 8 hours.
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fasting state at about 3 hours can be between about 22.0 and about 59.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 3 hours can be at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL, at least 26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/mL, at least 29.0 ng/mL, at least 30.0 ng/mL, at least 31.0 ng/mL, at least 32.0 ng/mL, at least 33.0 ng/mL, at least 34.0 ng/mL, at least 35.0 ng/mL, at least 36.0 ng/mL, at least 37.0 ng/mL, at least 38.0 ng/mL, at least
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 3 hours can be less than 59.0 ng/mL, less than 58.0 ng/mL, less than 57.0 ng/mL, less than 56.0 ng/mL, less than 55.0 ng/mL, less than 54.0 ng/mL, less than 53.0 ng/mL, less than 52.0 ng/mL, less than 51.0 ng/mL, less than 50.0 ng/mL, less than 49.0 ng/mL, less than 48.0 ng/mL, less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fasting state at about 4 hours can be between about 20.0 and about 56.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 4 hours can be at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL, at least 26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/mL, at least 29.0 ng/mL, at least 30.0 ng/mL, at least 31.0 ng/mL, at least 32.0 ng/mL, at least 33.0 ng/mL, at least 34.0 ng/mL, at least 35.0 ng/mL, at least 36.0 ng/mL, at least 37.0
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 4 hours can be less than 56.0 ng/mL, less than 55.0 ng/mL, less than 54.0 ng/mL, less than 53.0 ng/mL, less than 52.0 ng/mL, less than 51.0 ng/mL, less than 50.0 ng/mL, less than 49.0 ng/mL, less than 48.0 ng/mL, less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL, less than 37.0 ng/mL, less than 36.0 ng/mL, less than 35.0 ng/mL, less
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fasting state at about 6 hours can be between about 11.0 and about 47.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 6 hours can be at least 11.0 ng/mL, at least 12.0 ng/mL, at least 13.0 ng/mL, at least 14.0 ng/mL, at least 15.0 ng/mL, at least 16.0 ng/mL, at least 17.0 ng/mL, at least 18.0 ng/mL, at least 19.0 ng/mL, at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL, at least 26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 6 hours can be less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL, less than 37.0 ng/mL, less than 36.0 ng/mL, less than 35.0 ng/mL, less than 34.0 ng/mL, less than 33.0 ng/mL, less than 32.0 ng/mL, less than 31.0 ng/mL, less than 30.0 ng/mL, less than 29.0 ng/mL, less than 28.0 ng/mL, less than 27.0 ng/mL, less than 26.0 ng/mL, less
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fasting state at about 8 hours can be between about 7.0 and about 47.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 8 hours can be at least 7.0 ng/mL, at least 8.0 ng/mL, at least 9.0 ng/mL, at least 10.0 ng/mL, at least 11.0 ng/mL, at least 12.0 ng/mL, at least 13.0 ng/mL, at least 14.0 ng/mL, at least 15.0 ng/mL, at least 16.0 ng/mL, at least 17.0 ng/mL, at least 18.0 ng/mL, at least 19.0 ng/mL, at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng
- the plasma concentration of ivabradine after administration of the composition to a subject in the fasting state at about 8 hours can be less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than
- the mean plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fasting state at about 8 hours can be 20.0 to about 28.0 ng/mL.
- ivabradine After administration of the prolonged release composition to a subject in the fed state, ivabradine may have a peak plasma concentration between about 4 hours to about 10 hours.
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fed state at about 4 hours can be between about 11.0 and about 53.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 4 hours can be at least 11.0 ng/mL, at least 12.0 ng/mL, at least 13.0 ng/mL, at least 14.0 ng/mL, at least 15.0 ng/mL, at least 16.0 ng/mL, at least 17.0 ng/mL, at least 18.0 ng/mL, at least 19.0 ng/mL, at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL, at least 26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 4 hours can be less than 53.0 ng/mL, less than 52.0 ng/mL, less than 51.0 ng/mL, less than 50.0 ng/mL, less than 49.0 ng/mL, less than 48.0 ng/mL, less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL, less than 37.0 ng/mL, less than 36.0 ng/mL, less than 35.0 ng/mL, less than 34.0 ng/mL, less than 33.0 ng/mL, less than 32.0 ng/mL, less
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fed state at about 6 hours can be between about 24.0 and about 60.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 6 hours can be at least 24.0 ng/mL, at least 25.0 ng/mL, at least26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/mL, at least 29.0 ng/mL, at least 30.0 ng/mL, at least 31.0 ng/mL, at least 32.0 ng/mL, at least 33.0 ng/mL, at least 34.0 ng/mL, at least 35.0 ng/mL, at least 36.0 ng/mL, at least 37.0 ng/mL, at least 38.0 ng/mL, at least 39.0 ng/mL, at least 40.0 ng/mL, at least 41.0 ng/
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 6 hours can be less than 60.0 ng/mL, less than 59.0 ng/mL, less than 58.0 ng/mL, less than 57.0 ng/mL, less than 56.0 ng/mL, less than 55.0 ng/mL, less than 54.0 ng/mL, less than 53.0 ng/mL, less than 52.0 ng/mL, less than 51.0 ng/mL, less than 50.0 ng/mL, less than 49.0 ng/mL, less than 48.0 ng/mL, less than 47.0 ng/mL, less than 46.0 ng/mL, less than 45.0 ng/mL, less than 44.0 ng/mL, less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL,
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fed state at about 8 hours can be between about 13.0 and about 43.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 8 hours can be at least 14.0 ng/mL, at least 15.0 ng/mL, at least 16.0 ng/mL, at least 17.0 ng/mL, at least 18.0 ng/mL, at least 19.0 ng/mL, at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL, at least 26.0 ng/mL, at least 27.0 ng/mL, at least 28.0 ng/mL, at least 29.0 ng/mL, at least 30.0 ng/mL, at least 31.0 ng/
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 8 hours can be less than 43.0 ng/mL, less than 42.0 ng/mL, less than 41.0 ng/mL, less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL, less than 37.0 ng/mL, less than 36.0 ng/mL, less than 35.0 ng/mL, less than 34.0 ng/mL, less than 33.0 ng/mL, less than 32.0 ng/mL, less than 31.0 ng/mL, less than 30.0 ng/mL, less than 29.0 ng/mL, less than 28.0 ng/mL, less than 27.0 ng/mL, less than 26.0 ng/mL, less than 25.0 ng/mL, less than 24.0 ng/mL, less than 23.0 ng/mL, less than 22.0 ng/mL, less
- the plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fed state at about 10 hours can be between about 8.0 and about 40.0 ng/mL.
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 10 hours can be at least 8.0 ng/mL at least 9.0 ng/mL, at least 10.0 ng/mL, at least 11.0 ng/mL, at least 12.0 ng/mL, at least 13.0 ng/mL, at least 14.0 ng/mL, at least 15.0 ng/mL, at least 16.0 ng/mL, at least 17.0 ng/mL, at least 18.0 ng/mL, at least 19.0 ng/mL, at least 20.0 ng/mL, at least 21.0 ng/mL, at least 22.0 ng/mL, at least 23.0 ng/mL, at least 24.0 ng/mL, at least 25.0 ng/mL
- the plasma concentration of ivabradine after administration of the composition to a subject in the fed state at about 10 hours can be less than 40.0 ng/mL, less than 39.0 ng/mL, less than 38.0 ng/mL, less than 37.0 ng/mL, less than 36.0 ng/mL, less than 35.0 ng/mL, less than
- the mean plasma concentration of ivabradine after administration of the prolonged release composition to a subject in the fed state at about 10 hours can be about 21.0 to about 26.0 ng/mL.
- compositions can be used in methods of treating a disease or disorder in a subject in need thereof.
- the method may comprise administering the prolonged release composition to the subject in need thereof.
- the method may comprise administering the disclosed composition for once per day.
- Disorders in which a patient would benefit from treatment with the compositions disclosed herein include those which are associated with or accompanied by cardiac arrhythmia.
- the disease or disorder can be selected from the group consisting of chronic heart failure with systolic dysfunction, heart-related chest pain and heart failure.
- Use of the disclosed prolonged release composition can be suitable for the treatment of systolic dysfunction, heart-related chest pain and heart failure.
- additional therapeutic agent(s) can be administered simultaneously or sequentially with the disclosed compositions. Sequential administration includes administration before or after the disclosed compositions. In other embodiments, there can be an interval of time between administration of the additional therapeutic agent and the compositions. 5. Examples
- step 3 The wet granules obtained in step 2 were dried to get LOD between 2-3%.
- step 3 The dried granules of step 3 were passed through No. 30 sieve.
- step 5 Magnesium stearate was passed through No. 60 sieve and mixed with step 4 granules for 2 minutes. 6. The lubricated granules of step 5 were compressed in tablets.
- Magnesium stearate was sifted through No. 60 sieve and added to step 1 mixture and mixed for 1 minute 30 seconds.
- step 3 The lubricated blend of step 2 was compressed into tablets. 4. The dissolution of tablets was determined in 900 mL, 0.1N HC1, USP Type I, 50
- Ivabradine hydrochloride, polyvinylacetate/polyvinyl pyrrolidone and lactose anhydrous were sifted through No. 40 sieve and mixed in blender for 20 minutes.
- Magnesium stearate was sifted through No. 60 sieve and added to step 1 mixture and mixed for 1 minute 30 seconds.
- step 3 The lubricated blend of step 2 was compressed into tablets.
- Magnesium stearate was sifted through No. 60 sieve and added to step 1 mixture and mixed for 1 minute 30 seconds.
- step 3 The lubricated blend of step 2 was compressed into tablets. 4. The dissolution of tablets was determined in 900 mL, 0.1N HC1, USP Type I, 50
- Magnesium stearate was sifted through No. 60 sieve and added to step 1 mixture and mixed for 1 minute 30 seconds.
- step 3 The lubricated blend of step 2 was compressed into tablets. 4. Compressed tablets of step 3 were coated with the aqueous dispersion of colorant.
- the dissolution of tablets was determined in 900 ml, 0.1N HC1, USP Type I, 50 RPM.
- Table 8 Dissolution of Batch 11 under Dissolution Media with varying pH values (Volume 900ml, apparatus basket, 50 RPM)
- Ivabradine hydrochloride, dibasic calcium phosphate anhydrous and hydroxypropyl methylcellulose (HPMC) were sifted through No. 40 sieve and mixed.
- Magnesium stearate was sifted through No. 60 sieve and added to step 1 mixture and mixed.
- step 3 The lubricated blend of step 2 was compressed into tablets.
- step 3 Compressed tablets of step 3 were coated with the aqueous dispersion of colorant.
- Ivabradine hydrochloride, dibasic calcium phosphate anhydrous and hydroxypropyl methylcellulose (HPMC) were sifted through No. 40 sieve and mixed in blender for 20 minutes.
- Magnesium stearate was sifted through No. 60 sieve and added to stepl mixture and mixed for 3 minutes.
- step 3 The lubricated blend of step 2 was compressed into tablets.
- step 3 Compressed tablets of step 3 were coated with the aqueous dispersion of colorant.
- Table 10 Dissolution of Batch 16 in 900ml, 0.1N HC1, USP Type I, 50 RPM
- Ivabradine is rapidly released from immediate release tablets and is highly water soluble (>10mg/mL). Because of this, ivabradine is rapidly and almost completely absorbed after oral administration. However, ivabradine is eliminated with a half-life of about 2 hours in plasma and an effective half-life of 11 hours.
- the usual recommended starting dose of immediate release ivabradine is 5 mg twice daily. The maintenance dose should not exceed 7.5 mg twice daily.
- Test Product-T Ivabradine prolonged release tablet 15mg.
- Reference Product-R Coralan ® 7.5 mg (ivabradine hydrochloride) Tablets (Manufactured by Les Laboratories Servier Industries, France. Imported and Marketed in India by Serdia ® Pharmaceuticals Pvt. Ltd., Mumbai).
- a screening phase was carried out within 28 days prior to the scheduled dosing day of Period I.
- the subjects were administered the study drug in each period.
- the sequence of administration was determined by randomly. Based on the elimination half-life of ivabradine and N-desmethylated derivative, a washout period of 7 days was kept in between the dosing days of the study periods. The duration of the clinical part of the study was 30 days.
- test product After an overnight fast of at least 10 hours, a single oral dose (15 mg) of the test product was administered with 240 mL of drinking water at ambient temperature with the subjects in sitting posture.
- First dose After an overnight fast of at least 10 hours, a single oral dose (7.5 mg) of the reference product was administered with 240 mL of drinking water at ambient temperature with the subjects in sitting posture.
- Second dose After a fast of at least 2 hours at 12 hours of first dose, a single oral dose (7.5 mg) of the reference product was administered with 240 mL of drinking water at ambient temperature with the subjects in sitting posture.
- Test product After an overnight fast of at least 10 hours, the subjects were served a standardized high fat and high calorie vegetarian breakfast, which they consumed within 30 minutes. A single oral dose (15 mg) of the test product was administered to the subjects at 30 minutes after serving the breakfast. The IMP was administered in sitting posture with 240mL of drinking water at ambient temperature.
- First dose After an overnight fast of at least 10 hours, the subjects were served a standardized high fat and high calorie vegetarian breakfast, which they consumed within 30 minutes. A single oral dose (7.5mg) of the reference product was administered to the subjects at 30 minutes after serving the breakfast. The IMP was administered in sitting posture with
- Second dose After a fast of at least 2 hours at 12 hours of first dose, the subjects were served a standardized high fat and high calorie vegetarian meal, which they consumed within 30 minutes. A single oral dose (7.5mg) of the reference product was administered to the subjects at 30 minutes after serving the meal. The IMP was administered in sitting posture with 240 mL of drinking water at ambient temperature. B. Pharmacokinetics
- Each of the parameters are derived individually for each subject under fasting (Period I and Period II) and fed (Period III and Period IV) conditions from the plasma concentration vs. time profiles of ivabradine and N-desmethylated derivative (SI 8982) using non-compartmental model of Phoenix® WinNonlin® Version 6.4 (Certara L.P.).
- the maximum measured plasma concentration (C max ) and the time of observing the peak concentration (T max ) were calculated from the plasma concentration vs. time profile of the individual subjects.
- the units of C max and T max were ng/mL and hour (h) respectively.
- First order rate constant associated with the terminal (log-linear) portion of the curve was estimated via linear regression of time vs. log concentration.
- the terminal rate constant (l z ) parameter was calculated by linear least squares regression analysis using at least last three or more non- zero plasma concentration values.
- the unit of l z is hour 1 (1/h).
- Terminal half-life was calculated using the formula: 0.693/l z .
- AUC_%Extrap_obs(%) Residual area in percentage was determined by the formula: [( AUC0- ⁇ - AUC0-t)/AUC0- ⁇ ] x 100
- Tiag is the time prior to the first measurable (non-zero) plasma concentration.
- the unit of T lag is hour(h).
- Drug Concentration Measurements Venous blood samples were withdrawn at pre-dose (0 hour) and regular intervals following. The pre-dose blood samples were collected within a period of 60 minutes before the dosing. The post-dose in-house blood samples were collected within ⁇ 02 minutes from the scheduled time for all the subjects. For the reference product, a total of 31blood samples, each of 4mL were collected from each subject in respective period. For the test product, a total of 21 blood samples, each of 4mL were collected from each subject in respective period. [0094] The plasma samples of the subject were analyzed using an LC-MS/MS method with an 8-point calibration curve for ivabradine and N-desmethyl ivabradine.
- the plasma concentrations measured throughout the treatment sequences for ivabradine are shown in Tables A-D and summarized in the graphs in FIGS. 1A-1B.
- Tables A-D the plasma concentrations of ivabradine for the test product T1 (fasting conditions) is shown in Table A, test product T2 (fed conditions) in Table B, reference product R1 (fasting conditions) in Table C, and reference product R2 (fed conditions) in Table D.
- Table D The plasma concentrations measured throughout the treatment sequences for N- desmethyl ivabradine are shown in Tables E-H and summarized in the graphs in FIGS. 2A- 2B. With respect to the tables, the plasma concentrations of N-desmethyl ivabradine for the test product T1 (fasting conditions) is shown in Table E, test product T2 (fed conditions) is shown in Table F, reference product R1 (fasting conditions) is shown in Table G, and reference product R2 (fed conditions) is shown in Table H.
- T max and T lag are represented as median (min-max) value.
- T max and T lag are represented as median (min-max) value.
- the pharmacokinetic parameters of N-desmethyl ivabradine for Test Product-Tl and Reference Product-Rl under fasting conditions are summarized in Table 14 and the pharmacokinetic parameters of N-desmethyl ivabradine for Test Product-T2 and Reference Product- R2 under fed conditions are summarized in Table 15.
- Table 14 Descriptive Statistics of Formulation Means for N-Desmethyl Ivabradine under Fasting Conditions (Period and Period II)
- T max and T lag are represented as median (min-max) value.
- T max and T lag are represented as median (min-max) value.
- the plasma levels of ivabradine rose, after administration of the prolonged release formulations of this disclosure, for between about three to ten hours and then began to fall through a protracted, substantially linear decrease from the peak plasma level for the remainder of the twenty-four-hour period while maintaining at least a threshold therapeutic level of the drug during the entire twenty-four hour period.
- the conventional immediate release tablets give peak blood plasma levels in 0.5 to 2.5 hours.
- the maximum inhibition effect of heart rate reduction with respect to plasma concentration of ivabradine is comparable for all the formulations (Tl, T2, R1 and R2) which is ⁇ 10 beats/min.
- the prolonged release composition of the present disclosure when administered to healthy human volunteers provided a relatively flattened and steady plasma profile over 24 hours in comparison to conventional immediate release preparation of ivabradine products. Further, the prolonged release composition of the present disclosure when administered as single tablet per day maintained the comparable area under the plasma concentration vs time curve with that of two tablets (given 12 hours apart, 1 tablet morning and 1 tablet evening) of the conventional immediate release preparations.
- test product of this disclosure provided a method for obtaining flattened drug plasma concentration vs time profile, thereby affording a tighter plasma therapeutic range control than can be obtained with multiple daily dosing. Therefore, the administration of the prolonged release tablet eliminated the sharp peaks and troughs (hills and valleys) in blood plasma drug levels induced by multiple daily dosing with conventional immediate release tablets.
- the prolonged release composition of the present disclosure when administered as one tablet per day consecutively for 3 months was effective in stabilizing the heart rate when administered to patients suffering from congestive heart failure with systolic dysfunction, in contrast to conventional preparations which has to be administered as two tablets (one tablet morning and one tablet evening) for achieving the similar efficacy.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022009726A BR112022009726A2 (en) | 2019-11-19 | 2020-08-29 | PHARMACEUTICAL COMPOSITIONS FOR PROLONGED RELEASE OF IVABRADINE |
MX2022005932A MX2022005932A (en) | 2019-11-19 | 2020-08-29 | Prolonged release pharmaceutical compositions of ivabradine. |
PE2022000798A PE20221086A1 (en) | 2019-11-19 | 2020-08-29 | IVABRADINE PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS |
CONC2022/0007600A CO2022007600A2 (en) | 2019-11-19 | 2022-05-31 | Ivabradine Extended Release Pharmaceutical Compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921047196 | 2019-11-19 | ||
IN201921047196 | 2019-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021100056A1 true WO2021100056A1 (en) | 2021-05-27 |
Family
ID=72659842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2020/050753 WO2021100056A1 (en) | 2019-11-19 | 2020-08-29 | Prolonged release pharmaceutical compositions of ivabradine |
Country Status (5)
Country | Link |
---|---|
BR (1) | BR112022009726A2 (en) |
CO (1) | CO2022007600A2 (en) |
MX (1) | MX2022005932A (en) |
PE (1) | PE20221086A1 (en) |
WO (1) | WO2021100056A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128525A2 (en) * | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
-
2020
- 2020-08-29 MX MX2022005932A patent/MX2022005932A/en unknown
- 2020-08-29 BR BR112022009726A patent/BR112022009726A2/en unknown
- 2020-08-29 WO PCT/IN2020/050753 patent/WO2021100056A1/en active Application Filing
- 2020-08-29 PE PE2022000798A patent/PE20221086A1/en unknown
-
2022
- 2022-05-31 CO CONC2022/0007600A patent/CO2022007600A2/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010128525A2 (en) * | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
Non-Patent Citations (3)
Title |
---|
"Cosmetic Ingredient Handbook", 1992, pages: 587 - 592 |
"Remington's Pharmaceutical Sciences", 1975, pages: 335 - 337 |
MCCUTCHEON'S, EMULSIFIERS & DETERGENTS, vol. 1, 1994, pages 236 - 239 |
Also Published As
Publication number | Publication date |
---|---|
BR112022009726A2 (en) | 2022-08-09 |
PE20221086A1 (en) | 2022-07-05 |
MX2022005932A (en) | 2022-06-22 |
CO2022007600A2 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6303607B1 (en) | Method for administering a sustained release ranolanolazine formulation | |
US6479496B1 (en) | Methods for treating angina with ranolazine | |
US20170224666A9 (en) | Immediate-release tablet formulations of a thrombin receptor antagonist | |
US20080026050A1 (en) | Solid dose formulations of a thrombin receptor antagonist | |
WO2021100056A1 (en) | Prolonged release pharmaceutical compositions of ivabradine | |
WO2020089761A1 (en) | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof | |
US10945960B2 (en) | Celecoxib and amlodipine formulation and method of making the same | |
US20040009971A1 (en) | Use of alprazolam in treatment of disorders of the central nervous system | |
DE3736866A1 (en) | MEANS FOR THE TREATMENT OF HYPERTENSION AND HEART FAILURE | |
EP3335703A1 (en) | Pharmaceutical composition comprising omarigliptin | |
EP3431078B1 (en) | Non-pulsatile prolonged-release betahistine oral solid compositions | |
US8377979B2 (en) | Pharmaceutical formulation containing phenytoin sodium and magnesium stearate | |
KR20110056071A (en) | Composition for oral disitegrating tablets comprising olanzapine, and tablets manufactured therefrom | |
US20120028976A1 (en) | Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist | |
KR20130025851A (en) | Tablet quickly disintegrating containg megestrol and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20781106 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022009726 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022009726 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220518 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20781106 Country of ref document: EP Kind code of ref document: A1 |